InvestorsHub Logo
Followers 2
Posts 253
Boards Moderated 0
Alias Born 06/04/2007

Re: None

Tuesday, 05/02/2017 9:06:00 PM

Tuesday, May 02, 2017 9:06:00 PM

Post# of 1874
Just listened to Matt's presentation at the Bloom Burton conference from today and it explains the bump/reversal today. Finally some very frank open talk about interest from Pharma, multiple deals being worked on both global and regional and a confidence that is refreshing to hear. Somebody pinch me.

Looks like giving up the Japan market may be the best way to make the first registration pathway happen without little dilution. The burn rate was $1 mil /Month as almost all clinical programs have been halted to focus on regulatory and business deals.

Very impressive clinical results and an ASCO presentation coming up that seems to suggest that Reolysin can potentiate the effects of the best-selling cancer drugs today. Manufacturing needs a bump in scale but that is great to hear that at the 100 Liter scale 30 batches would be needed per year to service the breast cancer market if I heard him right. Matt led the bump in scale last time and I feel he is the right person to lead the company in the near term until a partner (or partners) are named.

Given all the stock I own and having been an owner for more than 10 years, I never thought I'd be thinking of buying more but I find it hard to resist lowering my current underwater holding basis at this point.

Any thoughts from people that have been here a while?

onco_investor

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent ONCY News